1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next

 
• By Jessica Merrill

The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.

Building Blocks
Biohaven is building out a long-term growth strategy • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd.'s first commercial product, Nurtec ODT (rimegepant), is off to a solid start as the first and only CGRP inhibitor with US Food and Drug Administration approval for both acute treatment and prevention of migraine. As Biohaven focuses on expanding the drug’s use in both settings, it is also building out a pipeline of drugs to address additional neurological conditions, as investor focus turns to what comes next.

Nurtec ODT generated $92.9m in second quarter sales, Biohaven reported on 9 August. The drug is the company’s first commercial product, and Biohaven is competing in a crowded category that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapy Areas

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.